Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Deferred Revenue: 2011-2017

Historic Current Deferred Revenue for Altimmune (ALT) over the last 5 years, with Dec 2017 value amounting to $19,753.

  • Altimmune's Current Deferred Revenue rose 780.64% to $173,952 in Q3 2018 from the same period last year, while for Sep 2018 it was $173,952, marking a year-over-year increase of 780.64%. This contributed to the annual value of $19,753 for FY2017, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2017, Altimmune's Current Deferred Revenue is $19,753, which was down 0.00% from $19,753 recorded in FY2016.
  • Over the past 5 years, Altimmune's Current Deferred Revenue peaked at $341,723 during FY2013, and registered a low of $19,753 during FY2016.
  • For the 2-year period, Altimmune's Current Deferred Revenue averaged around $19,753, with its median value being $19,753 (2017).
  • Data for Altimmune's Current Deferred Revenue shows a maximum YoY slumped of 75.27% (in 2013) over the last 5 years.
  • Over the past 3 years, Altimmune's Current Deferred Revenue (Yearly) stood at $341,723 in 2013, then reached $19,753 in 2016, then remained steady at $19,753 in 2017.